Symbols / QNRX
QNRX Chart
About
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 14.13M |
| Enterprise Value | 253.70M | Income | -13.77M | Sales | — |
| Book/sh | -2.06 | Cash/sh | 0.18 | Dividend Yield | — |
| Payout | 0.00% | Employees | 3 | IPO | — |
| P/E | — | Forward P/E | -1.57 | PEG | — |
| P/S | — | P/B | -4.23 | P/C | — |
| EV/EBITDA | -18.02 | EV/Sales | — | Quick Ratio | 0.94 |
| Current Ratio | 1.04 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -29.17 | EPS next Y | -5.55 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 08:00 | ROA | -99.47% |
| ROE | -6.51% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.62M |
| Shs Float | 3.16M | Short Float | 1.77% | Short Ratio | 0.72 |
| Short Interest | — | 52W High | 41.80 | 52W Low | 5.01 |
| Beta | 1.87 | Avg Volume | 55.77K | Volume | 63.77K |
| Target Price | $40.67 | Recom | None | Prev Close | $8.19 |
| Price | $8.74 | Change | 6.72% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$40.67
Mean price target
2. Current target
$8.74
Latest analyst target
3. DCF / Fair value
$-63.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.74
Low
$25.00
High
$70.00
Mean
$40.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-03-15 | main | Maxim Group | Buy → Buy | $4 |
- Quoin (NASDAQ: QNRX) to make clinical/stability batches after 4% and 5% rapamycin loads - Stock Titan ue, 11 Nov 2025 08
- (QNRX) Risk Channels and Responsive Allocation - Stock Traders Daily Sat, 21 Feb 2026 13
- Insider Purchase: Director at $QNRX Buys 15,152 Shares | QNRX Stock News - Quiver Quantitative Wed, 15 Oct 2025 07
- QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? - Stocktwits ue, 11 Nov 2025 08
- Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com Fri, 10 Oct 2025 07
- Quoin Pharmaceuticals sees significant stock increase - Intellectia AI ue, 17 Feb 2026 20
- Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On? - Benzinga Fri, 10 Oct 2025 07
- Here’s Why Quoin Pharmaceuticals Stock (QNRX) Exploded Today - TipRanks Fri, 10 Oct 2025 07
- This Quoin Pharmaceuticals Insider Increased Their Holding By 1,515,200% Last Year - simplywall.st Fri, 30 Jan 2026 08
- Quoin Pharmaceuticals (QNRX) Stock Skyrockets 140% on $104.5M Private Placement Deal - CoinCentral Fri, 10 Oct 2025 07
- Up to $104.5M: Quoin Pharmaceuticals Secures Private Placement with 7.98M ADS Warrants - Stock Titan Fri, 10 Oct 2025 07
- $QNRX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative Wed, 17 Dec 2025 08
- QNRX Stock Soars 300% After $104.5M Financing Through Private Placement - Stocktwits Fri, 10 Oct 2025 07
- Quoin Pharmaceuticals stock soars after achieving target rapamycin loadings - Investing.com ue, 11 Nov 2025 08
- (QNRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily ue, 10 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15152 | 212886 | — | Purchase at price 14.05 per share. | LANGER DENNIS H | Director | — | 2025-10-14 00:00:00 | D |
| 1 | 122221 | 54999 | — | Purchase at price 0.45 per share. | DUNN GORDON | Chief Financial Officer | — | 2024-12-23 00:00:00 | D |
| 2 | 555556 | 250000 | — | Purchase at price 0.45 per share. | CARTER DENISE P | Chief Operating Officer | — | 2024-12-23 00:00:00 | D |
| 3 | 28856 | 23205 | — | Purchase at price 0.71 - 0.91 per share. | DUNN GORDON | Chief Financial Officer | — | 2024-09-10 00:00:00 | D |
| 4 | 37735 | 28737 | — | Purchase at price 0.63 - 0.80 per share. | CARTER DENISE P | Chief Operating Officer | — | 2024-09-04 00:00:00 | D |
| 5 | 37894 | 28916 | — | Purchase at price 0.62 - 0.80 per share. | MYERS MICHAEL | Chief Executive Officer | — | 2024-09-04 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -9.44M | -9.27M | -8.98M | -20.27M |
| TotalUnusualItems | 7.50K | -2.68K | 417.31K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 7.50K | -2.68K | 417.31K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.96M | -8.69M | -9.38M | -21.46M |
| ReconciledDepreciation | 100.00K | 103.71K | 104.04K | 104.04K |
| EBITDA | -9.43M | -9.27M | -8.56M | -20.27M |
| EBIT | -9.53M | -9.38M | -8.67M | -20.37M |
| NetInterestIncome | 558.49K | 694.61K | -618.34K | -1.37M |
| InterestExpense | 0.00 | 714.08K | 1.09M | |
| InterestIncome | 558.49K | 694.61K | 95.75K | 0.00 |
| NormalizedIncome | -8.97M | -8.68M | -9.80M | -21.46M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.96M | -8.69M | -9.38M | -21.46M |
| TotalExpenses | 9.53M | 9.38M | 9.26M | 6.06M |
| DilutedAverageShares | 133.96K | 25.74K | 5.77K | 1.60K |
| BasicAverageShares | 133.96K | 25.74K | 5.77K | 1.60K |
| DilutedEPS | -66.85 | -337.47 | -1.64K | -28.54K |
| BasicEPS | -66.85 | -337.47 | -1.64K | -28.54K |
| DilutedNIAvailtoComStockholders | -8.96M | -8.69M | -9.45M | -21.46M |
| NetIncomeCommonStockholders | -8.96M | -8.69M | -9.45M | -21.46M |
| OtherunderPreferredStockDividend | 0.00 | 65.27K | 0.00 | |
| NetIncome | -8.96M | -8.69M | -9.38M | -21.46M |
| NetIncomeIncludingNoncontrollingInterests | -8.96M | -8.69M | -9.38M | -21.46M |
| NetIncomeContinuousOperations | -8.96M | -8.69M | -9.38M | -21.46M |
| PretaxIncome | -8.96M | -8.69M | -9.38M | -21.46M |
| OtherIncomeExpense | 7.50K | -2.68K | 494.54K | -14.03M |
| OtherNonOperatingIncomeExpenses | 77.24K | -14.03M | ||
| SpecialIncomeCharges | 0.00 | 416.00K | 0.00 | |
| OtherSpecialCharges | -416.00K | |||
| GainOnSaleOfSecurity | 7.50K | -2.68K | 1.31K | -1.25M |
| NetNonOperatingInterestIncomeExpense | 558.49K | 694.61K | -618.34K | -1.37M |
| TotalOtherFinanceCost | 275.00K | |||
| InterestExpenseNonOperating | 0.00 | 714.08K | 1.09M | |
| InterestIncomeNonOperating | 558.49K | 694.61K | 95.75K | 0.00 |
| OperatingIncome | -9.53M | -9.38M | -9.26M | -6.06M |
| OperatingExpense | 9.53M | 9.38M | 9.26M | 6.06M |
| ResearchAndDevelopment | 3.60M | 3.31M | 2.67M | 1.56M |
| SellingGeneralAndAdministration | 5.93M | 6.07M | 6.58M | 4.50M |
| GeneralAndAdministrativeExpense | 5.93M | 6.07M | 6.58M | 4.50M |
| OtherGandA | 5.93M | 6.07M | 6.58M | 4.50M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 44.00 | 44.00 | |
| OrdinarySharesNumber | 8.95M | 987.22K | 403.84K | 55.91K |
| ShareIssued | 8.95M | 987.22K | 403.88K | 55.95K |
| TangibleBookValue | 8.72M | 5.08M | 6.70M | -151.57K |
| InvestedCapital | 9.20M | 5.66M | 7.41M | 657.03K |
| WorkingCapital | 10.75M | 7.70M | 9.84M | 3.62M |
| NetTangibleAssets | 8.72M | 5.08M | 6.70M | -151.57K |
| CommonStockEquity | 9.20M | 5.66M | 7.41M | 657.03K |
| TotalCapitalization | 9.20M | 5.66M | 7.41M | 657.03K |
| TotalEquityGrossMinorityInterest | 9.20M | 5.66M | 7.41M | 657.03K |
| StockholdersEquity | 9.20M | 5.66M | 7.41M | 657.03K |
| TreasuryStock | 0.00 | 2.93M | 2.93M | |
| RetainedEarnings | -55.17M | -46.20M | -37.52M | -28.07M |
| AdditionalPaidInCapital | 64.37M | 51.87M | 47.86M | 31.66M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 6.50M | 6.51M | 7.05M | 8.70M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.32M | 2.92M | 3.52M | 4.12M |
| DuetoRelatedPartiesNonCurrent | 2.32M | 2.92M | 3.52M | 4.12M |
| TradeandOtherPayablesNonCurrent | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 4.18M | 3.58M | 3.53M | 4.58M |
| OtherCurrentLiabilities | 373.60K | |||
| PayablesAndAccruedExpenses | 4.18M | 3.58M | 3.53M | 4.20M |
| CurrentAccruedExpenses | 2.60M | 2.36M | 2.16M | 2.48M |
| InterestPayable | 1.15M | 1.15M | 1.15M | 743.84K |
| Payables | 1.58M | 1.22M | 1.37M | 1.72M |
| DuetoRelatedPartiesCurrent | 600.00K | 600.00K | 600.00K | 600.00K |
| TotalTaxPayable | 77.73K | 93.99K | 159.59K | 199.58K |
| AccountsPayable | 905.70K | 526.52K | 605.60K | 923.24K |
| TotalAssets | 15.71M | 12.17M | 14.46M | 9.36M |
| TotalNonCurrentAssets | 783.33K | 883.33K | 1.09M | 1.16M |
| OtherNonCurrentAssets | 50.00K | |||
| NonCurrentPrepaidAssets | 300.00K | 300.00K | 383.39K | 300.00K |
| GoodwillAndOtherIntangibleAssets | 483.33K | 583.33K | 704.56K | 808.60K |
| OtherIntangibleAssets | 483.33K | 583.33K | 704.56K | 808.60K |
| CurrentAssets | 14.93M | 11.29M | 13.37M | 8.20M |
| CurrentDeferredAssets | 0.00 | 32.58K | 0.00 | 0.00 |
| PrepaidAssets | 869.13K | 558.45K | 516.58K | 715.47K |
| CashCashEquivalentsAndShortTermInvestments | 14.06M | 10.69M | 12.85M | 7.48M |
| OtherShortTermInvestments | 10.43M | 8.29M | 9.99M | 0.00 |
| CashAndCashEquivalents | 3.62M | 2.40M | 2.86M | 7.48M |
| CashFinancial | 2.86M | 7.48M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.86M | -7.86M | -8.73M | -6.35M |
| RepaymentOfDebt | 0.00 | -311.67K | 0.00 | |
| IssuanceOfDebt | 0.00 | 3.48M | ||
| CapitalExpenditure | -250.00K | -625.00K | ||
| InterestPaidSupplementalData | 0.00 | 393.61K | ||
| EndCashPosition | 3.62M | 2.40M | 2.86M | 7.48M |
| BeginningCashPosition | 2.40M | 2.86M | 7.48M | 323.83K |
| ChangesInCash | 1.22M | -459.43K | -4.62M | 7.16M |
| FinancingCashFlow | 10.97M | 5.22M | 14.01M | 13.50M |
| CashFlowFromContinuingFinancingActivities | 10.97M | 5.22M | 14.01M | 13.50M |
| NetOtherFinancingCharges | 10.97M | 5.22M | 14.32M | 10.03M |
| NetIssuancePaymentsOfDebt | 0.00 | -311.67K | 3.48M | |
| NetShortTermDebtIssuance | 0.00 | -311.67K | 3.48M | |
| ShortTermDebtPayments | 0.00 | -311.67K | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 3.48M | ||
| NetLongTermDebtIssuance | 3.48M | |||
| LongTermDebtIssuance | 3.48M | |||
| InvestingCashFlow | -1.89M | 2.19M | -10.15M | -625.00K |
| CashFlowFromContinuingInvestingActivities | -1.89M | 2.19M | -10.15M | -625.00K |
| NetInvestmentPurchaseAndSale | -1.89M | 2.19M | -9.90M | 0.00 |
| SaleOfInvestment | 15.37M | 20.28M | 0.00 | |
| PurchaseOfInvestment | -17.25M | -18.09M | -9.90M | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | -250.00K | -625.00K | |
| PurchaseOfIntangibles | 0.00 | -250.00K | -625.00K | |
| OperatingCashFlow | -7.86M | -7.86M | -8.48M | -5.72M |
| CashFlowFromContinuingOperatingActivities | -7.86M | -7.86M | -8.48M | -5.72M |
| ChangeInWorkingCapital | -2.14K | 95.45K | -94.35K | 632.33K |
| ChangeInPayablesAndAccruedExpense | 275.95K | 53.92K | -217.81K | 1.35M |
| ChangeInAccruedExpense | 696.80K | |||
| ChangeInInterestPayable | 696.80K | |||
| ChangeInPayable | 275.95K | 53.92K | -217.81K | 1.35M |
| ChangeInAccountPayable | 275.95K | 53.92K | -217.81K | 1.35M |
| ChangeInPrepaidAssets | -278.09K | 41.52K | 123.45K | -715.47K |
| OtherNonCashItems | 714.08K | 2.22M | ||
| StockBasedCompensation | 1.26M | 1.09M | 764.01K | 0.00 |
| UnrealizedGainLossOnInvestmentSecurities | -251.59K | -489.08K | -93.78K | 0.00 |
| AssetImpairmentCharge | 0.00 | 17.52K | 0.00 | |
| DepreciationAmortizationDepletion | 100.00K | 103.71K | 104.04K | 104.04K |
| DepreciationAndAmortization | 100.00K | 103.71K | 104.04K | 104.04K |
| AmortizationCashFlow | 100.00K | 103.71K | 104.04K | 104.04K |
| AmortizationOfIntangibles | 100.00K | 103.71K | 104.04K | 104.04K |
| OperatingGainsLosses | -493.24K | 12.78M | ||
| GainLossOnInvestmentSecurities | -77.24K | 12.78M | ||
| NetIncomeFromContinuingOperations | -8.96M | -8.69M | -9.38M | -21.46M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for QNRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|